139 related articles for article (PubMed ID: 35759882)
1. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.
Wu X; Liu Z; Gan C; Wei W; Zhang Q; Liu H; Que H; Su X; Yue L; He H; Ouyang L; Ye T
Bioorg Chem; 2022 Oct; 127():105965. PubMed ID: 35759882
[TBL] [Abstract][Full Text] [Related]
2. 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.
Vidadala RSR; Golkowski M; Hulverson MA; Choi R; McCloskey MC; Whitman GR; Huang W; Arnold SLM; Barrett LK; Fan E; Merritt EA; Van Voorhis WC; Ojo KK; Maly DJ
ACS Infect Dis; 2018 Apr; 4(4):516-522. PubMed ID: 29522315
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors.
Abdelgawad MA; Bakr RB; Alkhoja OA; Mohamed WR
Bioorg Chem; 2016 Jun; 66():88-96. PubMed ID: 27043178
[TBL] [Abstract][Full Text] [Related]
4. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
5. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Li Y; Xiong Y; Zhang G; Zhang L; Yang W; Yang J; Huang L; Qiao Z; Miao Z; Lin G; Sun Q; Niu T; Chen L; Niu D; Li L; Yang S
J Med Chem; 2018 Dec; 61(24):11398-11414. PubMed ID: 30480444
[TBL] [Abstract][Full Text] [Related]
6. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
7. Discovery of thieno[2,3-d]pyrimidin-4(3H)-one derivatives as a new class of ROCK inhibitors.
Miao Z; Sun YM; Zhao LY; Li YS; Wang YF; Nan JS; Qiao ZE; Li LL; Yang SY
Bioorg Med Chem Lett; 2020 Mar; 30(6):126966. PubMed ID: 32001136
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.
Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP
Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
Zhang CH; Zheng MW; Li YP; Lin XD; Huang M; Zhong L; Li GB; Zhang RJ; Lin WT; Jiao Y; Wu XA; Yang J; Xiang R; Chen LJ; Zhao YL; Cheng W; Wei YQ; Yang SY
J Med Chem; 2015 May; 58(9):3957-74. PubMed ID: 25835317
[TBL] [Abstract][Full Text] [Related]
10. Discovery of
Fanta BS; Lenjisa J; Teo T; Kou L; Mekonnen L; Yang Y; Basnet SKC; Hassankhani R; Sykes MJ; Yu M; Wang S
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049714
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.
Ran K; Zeng J; Wan G; He X; Feng Z; Xiang W; Wei W; Hu X; Wang N; Liu Z; Yu L
Eur J Med Chem; 2021 Aug; 220():113499. PubMed ID: 33940465
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
13. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors.
Jiang A; Liu Q; Wang R; Wei P; Dai Y; Wang X; Xu Y; Ma Y; Ai J; Shen J; Ding J; Xiong B
Molecules; 2018 Mar; 23(3):. PubMed ID: 29562726
[TBL] [Abstract][Full Text] [Related]
15. Development of pyrazolo[3,4-d]pyrimidin-4-one scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation.
Xie F; Zhou L; Ge C; Song X; Yan H
Bioorg Med Chem Lett; 2022 Aug; 70():128803. PubMed ID: 35598793
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G
Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
